Comparison of IL-10 gene promoter polymorphisms and haplotypes between high-grade squamous intraepithelial lesions or cervical cancer and negative cervical cytology.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Uterine Cervical Neoplasms*/genetics ; Uterine Cervical Neoplasms*/pathology ; Interleukin-10*/genetics ; Squamous Intraepithelial Lesions*/genetics ; Squamous Intraepithelial Lesions*/pathology ; Squamous Intraepithelial Lesions of the Cervix*/genetics ; Squamous Intraepithelial Lesions of the Cervix*/pathology ; Promoter Regions, Genetic* ; Haplotypes* ; Polymorphism, Single Nucleotide*; Humans ; Female ; Adult ; Case-Control Studies ; Genetic Predisposition to Disease ; Middle Aged ; Gene Frequency ; Genotype

Cervical cancer, a leading cancer among women, is strongly associated with Human Papillomavirus infection, but host genetic factors also contribute to the progression from high-grade squamous intraepithelial lesions (HSIL) to invasive cancer. Interleukin-10 (IL-10), an immunosuppressive cytokine, may influence susceptibility to HSIL and cervical cancer through genetic variations. This study aimed to compare IL-10 gene promoter polymorphisms, -1082 A > G and - 819T > C, in women diagnosed with HSIL or cervical cancer and those with negative for intraepithelial lesion or malignancy (NILM). In this case-control study, 309 women were analyzed, including 142 with HSIL or cervical cancer and 167 controls with NILM. Blood samples were collected for DNA extraction and genotyping of polymorphisms through PCR amplification. Statistical analyses included comparisons of genotype and allele frequencies, haplotype frequency, and assessments of Hardy-Weinberg equilibrium and linkage disequilibrium. The mean age was 33.4 years for cases and 41.7 years for controls (p < 0.05). For the - 1082 A > G polymorphism, the GG genotype was significantly associated with a decreased risk of HSIL and cervical cancer (p = 0.0266, OR = 0.35). Recessive model (GG vs. AA + AG) confirmed this association (p = 0.0045, OR = 0.29). AC/GC diplotype was associated with a 2-fold increased risk of cervical lesions. Further studies are needed to confirm our results.
(© 2025. The Author(s).)

Declarations. Competing interests: The authors declare no competing interests.

Int J Cancer. 2001 Dec 15;94(6):792-4. (PMID: 11745479)
Scand J Immunol. 2012 Mar;75(3):273-81. (PMID: 22050574)
J Cancer Res Clin Oncol. 2020 Aug;146(8):1971-1978. (PMID: 32447484)
Nucleic Acids Res. 1988 Feb 11;16(3):1215. (PMID: 3344216)
Nucleic Acids Res. 2020 Jan 8;48(D1):D835-D844. (PMID: 31777943)
BMC Bioinformatics. 2023 Mar 6;24(1):79. (PMID: 36879236)
Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:282-90. (PMID: 16343245)
Cancer Lett. 2016 Oct 10;381(1):156-64. (PMID: 27431309)
J Exp Med. 1996 Aug 1;184(2):579-84. (PMID: 8760811)
J Pathol. 2001 Sep;195(2):179-85. (PMID: 11592096)
Hum Mol Genet. 2008 Oct 15;17(R2):R116-21. (PMID: 18852199)
Transplantation. 2003 Mar 15;75(5):711-7. (PMID: 12640314)
Jpn J Clin Oncol. 2010 Nov;40(11):1113-6. (PMID: 20558465)
Breast Cancer Res Treat. 2012 May;133(1):11-21. (PMID: 22057973)
Cancer Res. 2012 Jan 15;72(2):420-9. (PMID: 22123924)
Ann Hum Biol. 2016 May;43(3):261-8. (PMID: 26079218)
Microorganisms. 2021 Oct 03;9(10):. (PMID: 34683414)
J Int Med Res. 2014 Dec;42(6):1193-201. (PMID: 25281063)
Cell Biochem Biophys. 2015 Jan;71(1):77-84. (PMID: 25069725)
Oncol Lett. 2015 Mar;9(3):1015-1026. (PMID: 25663851)
Int J Gynecol Cancer. 2013 Jan;23(1):126-33. (PMID: 23095823)
Eur J Immunogenet. 1997 Feb;24(1):1-8. (PMID: 9043871)
Am J Epidemiol. 2009 Feb 15;169(4):505-14. (PMID: 19126586)
Science. 2002 Apr 12;296(5566):261-2. (PMID: 11954565)
Int Immunopharmacol. 2019 Jan;66:154-161. (PMID: 30453149)
Br J Cancer. 2021 Feb;124(4):831-841. (PMID: 33257839)
Int Immunopharmacol. 2020 Dec;89(Pt B):107091. (PMID: 33069925)
J Carcinog. 2003 May 16;2(1):3. (PMID: 12809559)
PLoS One. 2013;8(2):e57246. (PMID: 23460834)
Genet Mol Res. 2016 Aug 05;15(3):. (PMID: 27525910)
Cancer Lett. 2002 Oct 8;184(1):57-63. (PMID: 12104048)
Oncotarget. 2018 Jan 12;9(15):12365-12375. (PMID: 29552317)
Immunogenetics. 1997;46(2):120-8. (PMID: 9162098)
Nat Immunol. 2012 May 18;13(6):535-42. (PMID: 22610250)
Cytokine. 2019 Jan;113:99-104. (PMID: 29935877)
J Interferon Cytokine Res. 1999 Jul;19(7):697-703. (PMID: 10454339)
Clin Exp Immunol. 2013 May;172(2):263-79. (PMID: 23574323)
Tumour Biol. 2012 Oct;33(5):1549-56. (PMID: 22592655)
Infect Genet Evol. 2013 Oct;19:32-7. (PMID: 23800422)
Nature. 2015 Oct 1;526(7571):68-74. (PMID: 26432245)
Cytokine. 2015 Dec;76(2):343-347. (PMID: 26076679)
Cytokine. 2016 Jan;77:135-44. (PMID: 26579633)
Immunology. 2015 Sep;146(1):113-21. (PMID: 26059395)
Kidney Blood Press Res. 2017;42(1):89-98. (PMID: 28359052)
Front Immunol. 2023 Jun 08;14:1161067. (PMID: 37359549)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
J Interferon Cytokine Res. 2004 Apr;24(4):245-51. (PMID: 15144570)
Tumour Biol. 2015 Apr;36(4):2287-98. (PMID: 25412954)

Keywords: Interleukin-10; Polymorphism, single nucleotide; Uterine cervical neoplasms

130068-27-8 (Interleukin-10)
0 (IL10 protein, human)

Date Created: 20250803 Date Completed: 20250803 Latest Revision: 20250806

20260130

PMC12319095

10.1038/s41598-025-12851-5

40754553